Not known Facts About is nembutal a cns depressant
Not known Facts About is nembutal a cns depressant
Blog Article
pentobarbital will decrease the extent or outcome of lumacaftor/ivacaftor by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
pentobarbital will lessen the level or effect of lumefantrine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with strong CYP3A4 inducers can result in lowered serum concentrations and loss of antimalarial efficacy
pentobarbital will reduce the extent or influence of tacrolimus by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
pentobarbital will lessen the extent or influence of nateglinide by impacting hepatic enzyme CYP2C9/ten metabolism. Use Caution/Keep track of.
pentobarbital will reduce the extent or influence of isavuconazonium sulfate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
Keep track of Closely (two)pentobarbital will decrease the level or effect of suvorexant by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Strong CYP3A4 inducers may possibly lessen suvorexant efficacy; if greater suvorexant dose expected, never exceed twenty mg/day
fentanyl transdermal and pentobarbital both enhance sedation. Stay clear of or Use Alternate Drug. Limit use to individuals for whom choice procedure alternatives are insufficient
pentobarbital will lessen here the level or impact of dasatinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
pentobarbital and daridorexant both boost sedation. Modify Therapy/Monitor Carefully. Coadministration raises possibility of CNS melancholy, which can lead to additive impairment of psychomotor efficiency and lead to daytime impairment.
pentobarbital will lessen the extent or influence of norgestrel by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep an eye on Closely. Moderate CYP3A4 inducers might minimize progestin concentration; consider use of supplemental barrier procedures
pentobarbital will reduce the extent or impact of cilostazol by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.
pentobarbital will minimize the level or result of larotrectinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
Contraindicated (one)pentobarbital will decrease the level or result of cobimetinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Stay clear of coadministration. Potent or moderate CYP3A inducers could lower cobimetinib systemic publicity by >eighty% and decrease its efficacy.
Induction of microsomal enzymes by this drug, might shorten the half-lifetime of doxycycline for as long as two months soon after barbiturate therapy discontinued; check scientific response to doxycycline closely if both drugs administered concurrently